Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis
Authors
Keywords
-
Journal
CLINICAL PHARMACOKINETICS
Volume 51, Issue 7, Pages 443-455
Publisher
Springer Nature
Online
2012-05-01
DOI
10.2165/11599970-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
- (2011) T. Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Theoretical Analysis of Interplay of Therapeutic Protein Drug and Circulating Soluble Target: Temporal Profiles of ‘Free’ and ‘Total’ Drug and Target
- (2011) Cuyue Tang et al. PHARMACEUTICAL RESEARCH
- Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions
- (2010) P. ETTEHADI et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
- (2010) Yong Zhang et al. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
- Impact of Target-Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP-4 Inhibition in Type 2 Diabetic Patients
- (2010) Silke Retlich et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Transmembrane TNF- : structure, function and interaction with anti-TNF agents
- (2010) T. Horiuchi et al. RHEUMATOLOGY
- Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: A clinical randomized trial
- (2009) A. E. van der Bijl et al. ARTHRITIS AND RHEUMATISM
- On Setting the First Dose in Man: Quantitating Biotherapeutic Drug-Target Binding through Pharmacokinetic and Pharmacodynamic Models
- (2009) Philip J. Lowe et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
- (2009) Zehra Kaymakcalan et al. CLINICAL IMMUNOLOGY
- Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics
- (2009) Leonid Gibiansky et al. Expert Opinion on Drug Metabolism & Toxicology
- Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody
- (2009) Shweta R. Urva et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Target-mediated drug disposition model: relationships with indirect response models and application to population PK–PD analysis
- (2009) Leonid Gibiansky et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Development trends for therapeutic antibody fragments
- (2009) Aaron L Nelson et al. NATURE BIOTECHNOLOGY
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Approximations of the target-mediated drug disposition model and identifiability of model parameters
- (2008) Leonid Gibiansky et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Osteonecrosis and monoarticular rheumatoid arthritis treated with intra-articular adalimumab
- (2008) Senol Kobak Modern Rheumatology
- A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs
- (2007) Jasmine P. Davda et al. INTERNATIONAL IMMUNOPHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started